Google-backed Isomorphic Labs closed a $2.1 billion Series B to scale its AI drug-design engine and expand toward the clinic. The company positioned the engine as a unified design-and-development system rather than a software tool for licensing. The round is notable not only for size but for continued investor willingness to fund opaque program roadmaps, with Isomorphic maintaining partnerships with major pharma while investing in pipeline progress across oncology and immunology. For the sector, the financing signals that AI-first discovery organizations are consolidating fundraising power even as pharma expects more transparency on translational milestones.